Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.

Haeryfar SMM, Schell TD.

Cancer Immunol Immunother. 2018 Aug 21. doi: 10.1007/s00262-018-2231-z. [Epub ahead of print]

PMID:
30132082
2.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

3.

Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.

Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Avella DM, Fox T, Rockey DC, Schell TD, Kester M, Staveley-O'Carroll KF.

Gastroenterology. 2018 Mar;154(4):1024-1036.e9. doi: 10.1053/j.gastro.2017.10.050. Epub 2018 Jan 31.

4.

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD.

Oncoimmunology. 2017 Dec 21;7(3):e1405205. doi: 10.1080/2162402X.2017.1405205. eCollection 2018.

PMID:
29399407
5.

Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.

Ward-Kavanagh LK, Kokolus KM, Cooper TK, Lukacher AE, Schell TD.

Cancer Immunol Immunother. 2018 Apr;67(4):639-652. doi: 10.1007/s00262-018-2115-2. Epub 2018 Jan 13.

PMID:
29332158
6.

Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF.

Oncoimmunology. 2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017.

7.

Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer.

Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Brendle SA, Christensen ND, Schell TD, Hu J.

Sci Rep. 2017 Dec 5;7(1):16932. doi: 10.1038/s41598-017-17089-4.

8.

Effects of chronic alcohol consumption on DNA damage and immune regulation induced by the environmental pollutant dibenzo[a,l]pyrene in oral tissues of mice.

Chen KM, Schell TD, Richie JP Jr, Sun YW, Zhang SM, Calcagnotto A, Aliaga C, Gowda K, Amin S, El-Bayoumy K.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017 Oct 2;35(4):213-222. doi: 10.1080/10590501.2017.1391514. Epub 2017 Dec 4.

PMID:
29106334
9.

PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.

Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, Haeryfar SMM.

J Immunol. 2017 Nov 1;199(9):3348-3359. doi: 10.4049/jimmunol.1700643. Epub 2017 Sep 22.

PMID:
28939757
10.

Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function.

Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP Jr.

Eur J Clin Nutr. 2018 Jan;72(1):105-111. doi: 10.1038/ejcn.2017.132. Epub 2017 Aug 30.

PMID:
28853742
11.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

12.

TCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection.

Maru S, Jin G, Schell TD, Lukacher AE.

PLoS Pathog. 2017 Apr 14;13(4):e1006318. doi: 10.1371/journal.ppat.1006318. eCollection 2017 Apr.

13.

Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.

Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, Pameijer C, Neves RI, Anderson B, Kokolus KM, Mallon CA, Drabick JJ.

Cancer Biol Ther. 2017 Jan 2;18(1):36-42. doi: 10.1080/15384047.2016.1264543. Epub 2016 Dec 1.

14.

Malignant melanoma-The cradle of anti-neoplastic immunotherapy.

Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ.

Crit Rev Oncol Hematol. 2016 Oct;106:25-54. doi: 10.1016/j.critrevonc.2016.04.010. Epub 2016 May 7. Review.

PMID:
27637351
15.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD.

Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.

16.

Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, Li N, Yang QX, Kester M, Rountree CB, Kaifi JT, Cole DJ, Rockey DC, Schell TD, Staveley-O'Carroll KF.

J Hepatol. 2017 Jan;66(1):75-85. doi: 10.1016/j.jhep.2016.07.044. Epub 2016 Aug 9.

17.

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.

Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H.

Clin Cancer Res. 2016 Jun 15;22(12):3057-66. doi: 10.1158/1078-0432.CCR-15-2626. Epub 2016 Jan 13.

18.

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.

Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H.

Blood Cancer J. 2015 Jul 31;5:e330. doi: 10.1038/bcj.2015.58.

19.

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.

Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ.

Cancer Biol Ther. 2015;16(5):662-70. doi: 10.1080/15384047.2015.1026507.

20.

Purification of dendritic cell and macrophage subsets from the normal mouse small intestine.

Koscsó B, Gowda K, Schell TD, Bogunovic M.

J Immunol Methods. 2015 Jun;421:1-13. doi: 10.1016/j.jim.2015.02.013. Epub 2015 Mar 18.

PMID:
25796561
21.

Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.

Cozza EM, Cooper TK, Budgeon LR, Christensen ND, Schell TD.

Cancer Immunol Immunother. 2015 Mar;64(3):325-36. doi: 10.1007/s00262-014-1635-7. Epub 2014 Nov 19.

22.

Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.

Ward-Kavanagh LK, Zhu J, Cooper TK, Schell TD.

Cancer Immunol Res. 2014 Aug;2(8):777-88. doi: 10.1158/2326-6066.CIR-13-0164. Epub 2014 May 6.

23.

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.

Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE.

Eur J Nutr. 2015 Mar;54(2):251-63. doi: 10.1007/s00394-014-0706-z. Epub 2014 May 5.

PMID:
24791752
24.

Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase.

Rytelewski M, Meilleur CE, Yekta MA, Szabo PA, Garg N, Schell TD, Jevnikar AM, Sharif S, Singh B, Haeryfar SM.

PLoS One. 2014 Feb 28;9(2):e90439. doi: 10.1371/journal.pone.0090439. eCollection 2014.

25.

Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Goodwin EM, Zhong Q, Abendroth CS, Ward-Kavanagh LK, Schell TD, Cooper TK.

Comp Med. 2013 Aug;63(4):338-41.

26.

Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Watson AM, Mylin LM, Thompson MM, Schell TD.

J Immunol. 2012 Dec 15;189(12):5549-60. doi: 10.4049/jimmunol.1102221. Epub 2012 Nov 21.

27.

CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion.

Wilson JJ, Pack CD, Lin E, Frost EL, Albrecht JA, Hadley A, Hofstetter AR, Tevethia SS, Schell TD, Lukacher AE.

J Immunol. 2012 May 1;188(9):4340-8. doi: 10.4049/jimmunol.1103727. Epub 2012 Mar 23.

28.

Differential regulation of simultaneous antitumor and alloreactive CD8(+) T-cell responses in the same host by rapamycin.

Maleki Vareki S, Harding MJ, Waithman J, Zanker D, Shivji AN, Rytelewski M, Mazzuca DM, Yekta MA, Chen W, Schell TD, Haeryfar SM.

Am J Transplant. 2012 Jan;12(1):233-9. doi: 10.1111/j.1600-6143.2011.03811.x. Epub 2011 Oct 25.

29.

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, Staveley-O'Carroll KF.

Hepatology. 2012 Jan;55(1):141-52. doi: 10.1002/hep.24652.

30.

Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach.

Campbell C, Zhang R, Haley JS, Liu X, Loughran T, Schell TD, Albert R, Thakar J.

Front Physiol. 2011 Jul 11;2:32. doi: 10.3389/fphys.2011.00032. eCollection 2011.

31.

Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Hu J, Schell TD, Peng X, Cladel NM, Balogh KK, Christensen ND.

J Vaccines Vaccin. 2010 Aug 20;1(1). pii: 1000101.

32.

Poking CD40 for cancer therapy, another example of the Goldilocks effect.

Drabick JJ, Schell TD.

Cancer Biol Ther. 2010 Nov 15;10(10):994-6. Epub 2010 Nov 15. No abstract available.

PMID:
21057206
33.
34.

Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.

Tatum AM, Watson AM, Schell TD.

J Immunol. 2010 Sep 1;185(5):2763-72. doi: 10.4049/jimmunol.0903920. Epub 2010 Jul 26.

35.

Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease.

Manuel SL, Schell TD, Acheampong E, Rahman S, Khan ZK, Jain P.

J Leukoc Biol. 2009 Nov;86(5):1205-16. doi: 10.1189/jlb.0309172. Epub 2009 Aug 5.

36.

Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.

Ryan CM, Staveley-O'Carroll K, Schell TD.

J Immunother. 2008 Nov-Dec;31(9):906-20. doi: 10.1097/CJI.0b013e318189f155.

37.

CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2008 Sep 15;181(6):4406-17.

38.

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, van Tinteren H, Mesman EM, Song JY, Schumacher TN.

J Immunol. 2008 Aug 15;181(4):2563-71.

39.

An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants.

Tagaram HR, Watson AM, Lemonnier FA, Staveley-O'Carroll K, Tevethia SS, Schell TD.

Virology. 2008 Jun 20;376(1):183-90. doi: 10.1016/j.virol.2008.02.033. Epub 2008 Apr 10.

40.
42.

Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS.

Virology. 2007 Jul 20;364(1):155-68. Epub 2007 Mar 21.

43.

An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection.

Hu J, Peng X, Schell TD, Budgeon LR, Cladel NM, Christensen ND.

J Immunol. 2006 Dec 1;177(11):8037-45.

45.

Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors.

Sheil JM, Frankenberry MA, Schell TD, Brundage KM, Barnett JB.

Environ Health Perspect. 2006 Jul;114(7):1059-64.

47.

Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.

Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD.

J Immunol. 2005 Jul 15;175(2):700-12.

48.

Immune defects in 28-kDa proteasome activator gamma-deficient mice.

Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS Jr, Monaco JJ.

J Immunol. 2004 Mar 15;172(6):3948-54.

50.

Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected].

Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S.

J Immunol. 2003 Nov 1;171(9):4539-51. Erratum in: J Immunol. 2004 Jan 1;172(1):717.

Supplemental Content

Loading ...
Support Center